RecruitingPhase 4NCT06454188

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)

Sponsor

CARE ARTHRITIS LTD.

Enrollment

100 participants

Start Date

Dec 3, 2024

Study Type

INTERVENTIONAL

Conditions

Psoriatic Arthritis Spondyloarthritis, Axial

Summary

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Upadacitinib 15 MG [Rinvoq] for people with psoriatic arthritis and spondyloarthritis, axial. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUpadacitinib 15 MG [Rinvoq]

15mg tablet once per day.

DRUGPlacebo

15mg tablet once per day.

Locations(5)

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

The Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc.

Québec, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06454188

Related Trials

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT0686402655 locations